Contact the Editorial Team

Sending a note

Agility Peptide welcomes notes on the record: a citation quoted wrong, a regulatory reference gone out of date, or a peer-reviewed study on BPC-157, TB-500, GHK-Cu, or KLOW (or any of KLOW's four component peptides) that ought to join the references page. Corrections that sharpen the summaries are the most useful mail that lands here.

The notes easiest to act on give three things: the page they concern, the exact passage at issue, and the supporting citation — a DOI or PubMed ID wherever possible. That lets a proposed change be checked against its source right away.

Editorial mailbox: editors@agilitypeptide.com

Beyond the notebook's reach

So no message waits on an answer that will never come, a few things sit beyond what the site can address. Agility Peptide reads and summarizes literature; it is not a clinic and not a vendor, so it cannot:

• Advise on, endorse, or comment on human use of any peptide here.
• Name a dose, schedule, or route for any individual.
• Diagnose a condition or judge whether a finding fits a specific person.
• Sell, source, recommend, or help you locate any compound from any supplier.
• Answer athletes' questions about these compounds, given that BPC-157 (WADA S0) and TB-500 / the KLOW blend (WADA S2) are prohibited in sport.

Anyone seeking clinical guidance should consult a licensed clinician in their own jurisdiction. Replies to correspondence are not guaranteed and may be delayed; the mailbox is checked intermittently.